Comparison Chart Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
17.38 ^USD	+2.24%		+0.87%	-15.63%

02-04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5d. change	Varia. Jan 1.	1-year change	5-years change	Capi.	ST	MT	LT
	NEUROGENE INC.	Other Biotechnology & Medical Research	+2.24%	+0.87%	-15.63%	-5.65%	-	269M